Alzheimer's disease (AD) is the most common type of dementia among the elderly. 2 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
CT may be a viable secondary prevention technique for late-life depression, a group who are at risk of further cognitive decline and progression to dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Leukocyte telomere length (LTL) is considered as the marker of biological aging and may be related to environmental factors. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic conditions such as obesity, diabetes, and dementia are increasing in the United States (US) population. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Many studies have associated the Mediterranean diet with a decreased risk of dementia and AD, but a cause-and-effect relationship has not been deduced. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative diseases have reached alarming numbers in the past decade. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Several studies have shown that pharmacological and cognitive treatments for Alzheimers's disease improve cognitive function for short periods, but fewer studies have evaluated the efficacy of those treatments for longer (2-year) periods. 3 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source
Higher MD adherence is strongly associated with better cognitive status and less depressive symptomatology. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Tai Chi enhanced cognitive training effects in MCI. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Most prevalent neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease and multiple sclerosis are heterogeneous in their clinical profiles and underlying pathophysiology, although they typically share the presence of cognitive impairment that worsens significantly during the course of the disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The relationship between diet and cognitive function has been a topic of increasing interest, as numerous studies have shown that variations in dietary practices and nutrient intake may protect against age-related cognitive decline, as well as the development of dementia and Alzheimer's Disease (AD). 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
43/100
This prospective study found that high consumption of Western diet components attenuates benefits of the MedDiet on cognition. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) incidence is increasing worldwide at an alarming rate. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Over the past several years, increasing evidence suggests that the Mediterranean diet has a beneficial influence on several age-related diseases, showing protective effect on health and longevity. 2 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source
In the mature brain, chronic alcohol use disorders are associated with graded global brain dysmorphology. 3 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
Aberrations in hippocampal asymmetry and left hippocampal volumes were found for adolescent heavy drinkers. 5 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
In nondemented older persons, executive function is independently associated with tasks of lower extremity function that require high attentional demand. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
These findings show that sleep loss alters some plasma AD biomarkers by lowering brain clearance mechanisms and needs to be taken into account when interpreting individual plasma AD biomarkers but not ratios. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The sleep-wake cycle regulates interstitial fluid (ISF) and cerebrospinal fluid (CSF) levels of β-amyloid (Aβ) that accumulates in Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with greater early- and middle-life cognitive activity had lower [(11)C]PiB uptake. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Hippocampus is the significant component of the limbic lobe, which is further subdivided into the dentate gyrus and parts of Cornu Ammonis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We provide a brief review of the literature on exercise effects on brain and cognition. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
43/100
Given the aging populations in many countries throughout the world, there is an increasing interest in lifestyle factors and interventions that will enhance the cognitive vitality of older adults and reduce the risk for age-related neurological disorders, such as Alzheimer's disease. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Increased muscle mitochondria are largely responsible for the increased resistance to fatigue and health benefits ascribed to exercise training. 1 key finding →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
A number of factors, including physical activity, may contribute to prevention of cognitive decline and delay the onset of dementia. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,888 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Physical exercise in the prevention and treatment of Alzheimer's disease
- Metabolic Syndrome, Alzheimer's Disease, and Covid 19: A Possible Correlation
- Learning to remember: cognitive training-induced attenuation of age-related memory decline depends on sex and cognitive demand, and can transfer to untrained cognitive domains
- Long-term health benefits of physical activity--a systematic review of longitudinal studies
- Effects of restriction of activities and social isolation on risk of dementia in the community
- Dietary fish oil increases catalase activity in patients with probable Alzheimer's disease
- A change in sleep pattern may predict Alzheimer disease
- Relationships of peripheral IGF-1, VEGF and BDNF levels to exercise-related changes in memory, hippocampal perfusion and volumes in older adults
- Mediterranean Diet and Risk of Dementia
- The Gut Microbiota as a Mediator Linking the MIND Diet to Alzheimer’s Disease
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →